CLINICAL TRIAL

Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2024-01-24
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University Hospital Basel Switzerland

Watch author

Derived topics and classifications

psilocybin Brain Imaging Receptor Pharmacology Consciousness Aging Toxicity Qualitative Study

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy SubjectsClinicalTrials.gov · 2021-04-27 Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-25 Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of ConsciousnessClinicalTrials.gov · 2023-03-29 Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy SubjectsClinicalTrials.gov · 2025-03-05 Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced MeditatorsClinicalTrials.gov · 2023-09-21 Characterization of Altered Waking States of Consciousness in Healthy HumansClinicalTrials.gov · 2021-04-29 Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09